Skip to main content

Adagio Medical Holdings, Inc.

corporate_fare Company Profile

Adagio Medical Holdings, Inc.

ADGM·NASDAQ·Industrial Applications And Services·CIK 0002006986

Adagio Medical Holdings, Inc. is a medical device company that develops and sells products for treating cardiac arrhythmias using its proprietary catheter-based Ultra-Low Temperature Ablation ("ULTA") technology. This technology was previously known as Ultra-Low Temperature Cryoablation ("ULTC"). The company's primary focus is on treating ventricular tachycardia ("VT"), a fast, abnormal heart rhythm originating in the heart's lower chambers (ventricles). VT can impair blood flow and, if sustained, can be fatal, contributing to approximately 300,000 sudden cardiac deaths ("SCD") annually in the United States. Current Radio Frequency ("RF") ablation catheters used for VT were mainly designed and approved for atrial fibrillation ("AF"), making them less optimal for the specific anatomy and disease characteristics of the ventricle. This can lead to complex procedures and sub-optimal outcomes, potentially limiting market growth for VT ablations. Adagio Medical Holdings, Inc.'s clinically tested ULTA products are specifically designed for VT patients, addressing the unique ventricular anatomy and patient needs. The ULTA approach aims to create large, durable lesions that extend through both diseased and healthy muscular tissue of the ventricular myocardium, which the company hypothesizes will improve VT ablation effectiveness and patient outcomes. Their catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle using a stable, endocardial (inside the heart) approach without requiring irrigation. In October 2025, the company announced the completion of enrollment in its FULCRUM-VT Pivotal FDA Investigational Device Exemption ("IDE") study. This study evaluates the vCLAS™ Cryoablation System for ablating monomorphic ventricular tachycardia (MMVT) in patients with both ischemic and non-ischemic cardiomyopathy. The vCLAS System, which received Breakthrough Device Designation from the FDA in April 2025, is built on the proprietary ULTA technology platform and typically uses a double freeze cycle (freeze-thaw-freeze) protocol.

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 24 items for ADGM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Adagio Medical Details $19M Private Placement, Registers 68M Shares for Resale Amid Going Concern
  • Adagio Medical Details Highly Dilutive $19M Private Placement and Registers Over 31M Shares for Resale Amidst Going Concern Warning
  • Adagio Medical Reports FY25 Results with Going Concern Warning and Highly Dilutive $19M PIPE Financing
  • Adagio Medical Secures $19M Private Placement, Reports Strong Q4, and Advances Pivotal VT Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$25.08M
Diluted EPS
-$1.51
Op. Cash Flow
-$19.01M
Free Cash Flow
-$19.39M
Gross Profit
-$684K
Operating Income
-$21.89M
Cash & Equivalents
$17.11M
Total Debt
$21.04M
Debt / Equity
1.70×
Shares Outstanding
22.21M sh
Source: 10-K · filed 2026-07-13 · accession 0001104659-26-082769
$1.5 -1.32% today
52-week range · as of 2026-11-16 $1.5 – $50.7
Market cap
$1.72M
Volume
27.7K (0.2× avg)
3-mo avg 118.7K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADGM - Filings & News (Page 2)

ADGM
Mar 27, 2026, 8:48 AM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $1.50 info
Change: Reverse Stock Split info
Market Cap: $1.721M info
ADGM
Mar 27, 2026, 8:46 AM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.50 info
Change: Reverse Stock Split info
Market Cap: $1.721M info
ADGM
Mar 27, 2026, 8:42 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.50 info
Change: Reverse Stock Split info
Market Cap: $1.721M info
ADGM
Mar 27, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.50 info
Change: Reverse Stock Split info
Market Cap: $1.721M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets